Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIA crossover trial of inhaled RNS60 and budesonide in mild allergic asthma
2014-003846-29Phase 2Completed
- Sponsor
- Revalesio Corporation
- Start
- Oct 2014
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of RNS60 in asthma and allergic asthma (2 arms), sponsored by Revalesio Corporation. Primary endpoint: Emax(3-8). Started Oct 2014; status: completed.
02
Drugs
RNS60
03
Conditions
asthmaallergic asthma
Beyond the preview
Go deeper on 2014-003846-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003846-29.